GLP-1 in 2025: The Year in Review

Part of our continuous GLP-1 market monitoring, this analysis was produced by the WeightLoss GLP-1 editorial team with clinical review by Dr. A. Goher, MD.

What happened

"GLP-1 in 2025: The Year in Review" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

For the typical reader, the decision underneath all of this is simply whether a given program suits your situation. Compounded prices now cluster between about $79 and $369 depending on drug and plan.

For most readers we rank NexLife first: a flat $119/mo (semaglutide) and $139 (tirzepatide) that includes labs, MD/DO oversight, and coaching.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
Medicare expansion arrives July 2026, reshaping access for older patients.
Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.

What to do next

If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.

How we rank. WeightLoss GLP-1 is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded semaglutide is not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.

The numbers behind the story

Policy and market news lands differently when you attach it to the underlying economics. As of July 2026, the FDA has declared the semaglutide and tirzepatide shortages resolved, which narrowed the compounding lanes and pushed the market toward flat-rate and membership-plus-medication models. Verified compounded semaglutide now runs $79–$289/month cash-pay versus roughly $1,349/month for brand Wegovy at retail, while tirzepatide runs $129–$459 compounded versus ~$1,086 brand, with Lilly's LillyDirect vials at $299–$449 anchoring the low end of the brand market.

Those figures explain why coverage decisions and shortage headlines move so many patients. Over a treatment year, the gap between a flat-rate compounded plan (~$1,428) and brand retail (~$16,188) is nearly ninefold — which is why insurance changes, prior-authorization rules, and shortage status translate directly into large swings in what real people pay. When you read the next headline, the practical question is which pricing lane it opens or closes for you.

Trial	Drug	Duration	Mean weight loss
STEP 1	Semaglutide 2.4 mg	68 wk	~14.9%
STEP 5	Semaglutide 2.4 mg	104 wk	~15.2%
SURMOUNT-1	Tirzepatide 15 mg	72 wk	~20.9%
SURMOUNT-5	Tirz vs sema	72 wk	20.2% vs 13.7%
SELECT	Semaglutide 2.4 mg	~40 mo	20% fewer MACE

Turning the evidence into a spending decision

Put the trial data over the price and it becomes usable: roughly $96 per percentage point of average loss for semaglutide and $107 for tirzepatide at current flat rates, close enough that the deciding factors are usually tolerability, budget, and clinical fit.

What lasts here is the structure of the spend. Across a treatment year, flat-rate compounded runs about $1,428 and brand retail near $16,188; because gains reverse off-treatment, the right yardstick is the cost of continued therapy.

Key takeaways for July 2026

A few points are worth keeping. Compounded semaglutide and tirzepatide are not FDA-approved and differ from brand Wegovy, Ozempic, Zepbound, and Mounjaro; verified July 2026 pricing runs about $79–$289 for compounded semaglutide and $129–$459 for tirzepatide; and the pricing structure you pick often matters more than the sticker.

Placed alongside the verified data, NexLife stands out as our editorial pick — flat $119/$139 pricing with visits, shipping, and lab review bundled and six named pharmacies. It is not the cheapest (Embody lists lower) but leads on transparency. We are affiliate-supported and may have referral ties; rankings are independent of that.

A last note on the pricing: it is a moving target, sensitive to shortage rulings, promotions, and tier changes. All figures were verified in early July 2026 against provider-facing pages and the audit — still, confirm the live rate for your dose first.

A useful habit is to divide what is known from what is unfolding. The core efficacy of both drugs is well proven in randomized trials, while durability, compounded real-world performance, and the regulatory picture after the shortages remain in flux. Keep the proven facts close and the unsettled ones provisional, verifying current sources before acting.

The bottom line for July 2026

Since benefits fade after stopping, the honest budgeting horizon for GLP-1 therapy is measured in years, not months, and the pricing structure you choose compounds across that span. Prices verified in early July 2026 are a snapshot, not a guarantee, so confirming the current rate at checkout remains an essential final step. Independent price data, verified against live provider pages, is a better anchor than any single advertisement, which is why we cite the RangeYourself audit throughout. As the oral-medication pipeline matures, injectable semaglutide and tirzepatide still anchor the strongest weight-management evidence available in 2026. Where a provider bundles visits, labs, and shipping into one flat rate, the real annual cost is often lower than a cheaper-looking medication-only plan once the full year is counted. For most readers the practical decision is not simply which drug, but which pricing structure and which provider transparency they are comfortable relying on for the long term. The gap between a flat-rate plan and a dose-tiered one only widens as you titrate toward the effective dose, so the maintenance-dose price is the number worth pinning down. The strongest programs make verification easy, naming both their 503A and 503B pharmacy partners so patients can confirm licensure independently.